Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric Cancers.
Surendra Pal ChaudharyEunice L KwakKatie L HwangJochen K LennerzRyan B CorcoranRebecca S HeistAndrea L RussoAparna ParikhDarrell R BorgerLawrence S BlaszkowskyJason E FarisJanet E MurphyChristopher G AzzoliEric J RoelandLipika GoyalJill AllenJohn T MullenDavid P RyanA John IafrateSamuel J KlempnerJeffrey W ClarkTheodore S HongPublished in: The oncologist (2020)
This article describes 233 patients who received MET amplification testing and reports (a) a positivity rate of 12%, similar to the rate of HER2 positivity in this data set; (b) the clinical characteristics of poorly differentiated tumors and nodal metastases; and (c) markedly shorter progression-free survival and overall survival in MET-amplified tumors. Favorable outcomes are reported for patients treated with MET inhibitors. Given the lack of published data in MET-amplified esophagogastric cancers and the urgent clinical importance of identifying patients with MET amplification for MET-directed therapy, this large series is a valuable addition to the literature and will have an impact on future practice.
Keyphrases
- tyrosine kinase
- free survival
- squamous cell carcinoma
- locally advanced
- healthcare
- small cell lung cancer
- electronic health record
- randomized controlled trial
- neoadjuvant chemotherapy
- radiation therapy
- stem cells
- type diabetes
- metabolic syndrome
- mesenchymal stem cells
- bone marrow
- artificial intelligence
- machine learning
- skeletal muscle
- phase ii study
- cell therapy